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Abstract Zn is essential for growth and develop-
ment. The bioavailability of Zn is affected by several
factors such as other food components. It is therefore
of interest, to understand uptake mechanisms of Zn
delivering compounds to identify ways to bypass the
inhibitory effects of these factors. Here, we studied the
effect of Zn amino acid conjugates (ZnAAs) on the
bioavailabilty of Zn. We used Caco-2 cells and
enterocytes differentiated from human induced
pluripotent stem cells from a control and Acroder-
matitis enteropathica (AE) patient, and performed
fluorescence based assays, protein biochemistry and
atomic absorption spectrometry to characterize cellu-
lar uptake and absorption of ZnAAs. The results show
that ZnAAs are taken up by AA transporters, leading
to an intracellular enrichment of Zn mostly uninhib-
ited by Zn uptake antagonists. Enterocytes from AE
patients were unable to gain significant Zn through
exposure to ZnCl2 but did not show differences with
respect to ZnAAs. We conclude that ZnAAs may
possess an advantage over classical Zn supplements
such as Zn salts, as they may be able to increase
bioavailability of Zn, and may be more efficient in
patients with AE.
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Introduction
Research from the last decades clearly shows that Zn
has a vital role in neonatal and postnatal development,
and adult life. Zn is an essential trace element in
humans and animals, and is involved in countless
metabolic and signaling pathways within the body.
However, a particular role of Zn in the immune system
and brain has been reported (Prasad 2014).
Two major pools of Zn can be found within the
body. One pool that contains about 90% of the body’s
Zn is exchanging Zn slowly with the blood. The
second pool that rapidly exchanges Zn with the plasma
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contains the other 10% of Zn and is the one that is
especially reactive to the amount of absorbed Zn from
the diet (Hambidge et al. 1986). This Zn supply is
dependent on the amount and bioavailability of Zn. In
a western mixed diet consisting of commonly con-
sumed foods, the bioavailability of Zn is about
20–30% (Gallaher et al. 1998). Various compounds
and substances present in the diet can inhibit Zn
absorption. For example, phytates such as inositol
hexaphosphates and pentaphosphates bind to Zn and
reduce its availability (Lo¨nnerdal 2000; King 2007).
Further, high fructose corn syrup (HFCS) is able to
influence Zn absorption, as does Cu, which has an
antagonistic relationship with Zn (Hill and Matrone
1970; Mills 1985; Hall et al. 1979; Huster 2010).
Moreover, Ca and Fe might interfere with the absorp-
tion of Zn (Wood and Zheng 1997; Whiting andWood
1997; Argiratos and Samman 1994; O’Brien et al.
2000; Fischer Walker et al. 2005; Hambidge et al.
1983). Additionally, folic acid, a nutrient commonly
prescribed and supplied at higher levels during
pregnancy has been shown to decrease Zn absorption
(Ghishan et al. 1986; Simmer et al. 1987; Krebs 2000).
Regarding Zn in supplements, the bioavailability
can vary from very low (e.g. zinc oxide) to compar-
atively high (e.g. zinc salts such as zinc acetate) and is
influenced by multiple factors (competition with other
minerals as well as Zn itself supplied through dietary
sources, inhibition by food substances) (Lo¨nnerdal
et al. 1984). An ideal Zn supplier should therefore use
other routes as those potentially inhibited and satu-
rated by Zn and other competitive trace metals, such as
classical Zn transporters.
Here, we investigated uptake and absorption of
three compounds with Zn bound to amino acids
(ZnAAs): Zn-glutamate (ZnGlu), Zn-lysine (ZnLys)
and Zn-methionine (ZnMet). ZnAAs have been stud-
ied in the past. For example, it was shown that
100 ppm Zn from ZnAAs additional to 100 ppm Zn
from ZnSO4 in sow diets may increase pigs born and
weaned per litter (Payne et al. 2006), and that ZnMet
supplemented diet slightly improves intestinal mor-
phology of weaned pigs (Metzler-Zebeli et al. 2010).
Further, ZnAAs showed positive effects regarding
production parameters in dairy cows (Osorio et al.
2016; Nayeri et al. 2014), and a higher bioavailability
of Zn from ZnAA compared to Zn from ZnSO4 was
shown in broilers (Star et al. 2012). However, the
different possible routes of uptake of these ZnAAs
have not been investigated in detail so far.
Under physiological conditions, Zn is taken up
in the gastrointestinal (GI) tract into enterocytes by
Zn transporters of the Zrt- and Irt-like protein (ZIP/
SLC39A) family that mediate the uptake, while Zn
transporters of the Zinc Transporter (ZnT/SLC30A)
family mostly mediate removal. For example, the
ZIP4 (SLC39A4) transporter plays a major role in
Zn absorption in the small intestine (Cousins and
McMahon 2000). Mutations in ZIP4 may cause
Acrodermatitis enteropathica (AE), a rare and, if
left untreated, lethal autosomal recessive genetic
disorder of Zn uptake (Andrews 2008). The release
of Zn from enterocytes into the blood stream, in
turn, is mediated by ZnT1 (SLC30A1) (Cousins
2010).
Amino acids, for example from digested proteins,
are taken up by at least four sodium-dependent amino
acid transporters, and sodium-independent trans-
porters, mediating the uptake of acidic, basic, neutral
amino acids. We investigate Zn bound to glutamate
(Glu), lysine (Lys) andmethionine (Met). Glu is a non-
essential AA and classified as acidic AA. L-Lysine
(a,e-diaminocarpoic acid) and L-Methionine (2-
amino-4-(methylthio)butanoic acid) are essential
AAs. Lys is a basic AA, whereas Met belongs to the
hydrophobic AAs.
As in vitro model for Zn uptake and absorption, we
use the human intestinal cell line Caco-2. Caco-2 cells
have been used to assess Zn metabolism previously
(Zo¨dl et al. 2003) and are recognized by the FDA as a
validated model to study drug absorption in humans
(Corti et al. 2006). In addition, we use human
enterocytes differentiated from a healthy individual
and a patient with AE. For in vivo studies, we use
mouse models that were fed different diets containing
antagonists with and without ZnAAs for 8 weeks. The
Zn transporters in the intestines of mice and humans
are highly conserved not only in their sequence but
also the different isoforms. We hypothesized that Zn
linked to AAs might be taken up by AA transporters to
some extent and thus may ameliorate inhibition of Zn
absorption in the presence of antagonists.
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Results
Zn deficiency can be induced by uptake
antagonists in vivo
Rather than the total concentration, the bioavailability
of Zn in the diet plays a major role for the Zn status of
the body. As a proof of principle, we fed female wild
type C57BL/6 mice 3 different diets for 9 weeks. The
diet was started in 10 weeks old animals. Diet 1
(Control) was a standard laboratory diet containing all
necessary vitamins and minerals including 41 mg/kg
Zn, 0.72% Ca, 113 mg/kg Fe, 4.5 mg/kg phytates, and
0.7 mg/kg folic acid. Diet 2 (Zn deficient) was the
same standard laboratory diet except Zn was reduced
to 19 mg/kg. Diet 3 (Zn inhibitor) was a standard
laboratory diet containing the 41 mg/kg Zn, but with
increased levels of Zn uptake antagonists (1.13% Ca,
503 mg/kg Fe, 9.5 mg/kg phytates, and 1.9 mg/kg
folic acid). A complete list of ingredients can be found
as supplementary data (Supplementary Data 1).
Whole-blood Zn levels were investigated by AAS
in three animals per group (Fig. 1a). The results show
that animals on a Zn deficient diet (Diet 2) had
significantly reduced Zn levels compared to mice on
the control diet (Diet 1) (one-way ANOVA,
F = 8.740, p = 0.017, Post hoc analysis: Control vs.
Zinc deficient, p = 0.0461). Interestingly, mice on the
control diet that contained increased levels of Zn
uptake antagonists (Diet 3) showed a reduction in
blood-zinc levels similar to the mice on the Zn
deficient diet (Control vs. Zinc inhibitor, p = 0.0307).
Thus, despite adequate supply of Zn in the diet, the
presence of increased levels of Zn uptake antagonists
was sufficient to induce Zn deficiency in mice. To
overcome the antagonistic effects and thus to increase
bioavailability of Zn, delivery of Zn using ZnAAsmay
be a promising approach.
Zn from ZnAAs is taken up by AA transporters
in Caco-2 cells
In the ZnAAs used in this study, the complex with Zn
is formed between the amino acid group and the alpha
nitrogen. Thus, although the side group may increase
the stability, it is not needed for binding. In a first set of
experiments, we investigated the possibility to visu-
alize ZnAA complexes in cell free conditions by
fluorescent probes. To that end, we used Zinpyr1, a Zn
fluorophore that is able to bind to Zn found in complex
with an AA (Fig. S1b). To investigate Zn uptake from
ZnAA in vitro, and to characterize the uptake
pathways, we used the human intestinal cell line
Caco-2 since the intestine is the first tissue confronted
with large quantities of Zn. Caco-2 cells were
incubated for 30 min with ZnCl2 solution (50 lM)
or ZnAAs delivering an equivalent of 50 lM Zn. The
mean intracellular Zn concentration per cell was
determined by Zinpyr-1 fluorescence intensity. Zin-
pyr-1 is a membrane-permeant fluorescent sensor for
Zn with a high specificity and affinity (Kd =
0.7 ± 0.1 nM) (Burdette et al. 2001). However,
Zinpyr-1 does not only detected ‘‘free’’ but also
weakly protein bound Zn and the pool of Zn
detectable by Zinpyr-1 is measured. Further, the
content of Zn in ZnAA preparations was determined
by AAS (Fig. S1c). As ZnAA solutions were prepared
according to the MW of ZnAAs from powder that may
contain traces of moisture and bisulfate acting as Zn
donor in the production process, final concentrations
measured for ZnAAs were slightly lower as calculated
and the concentration of ZnAA used in the experi-
ments adjusted to deliver an equivalent of Zn
compared to Zn-delivery by ZnCl2 solution (50 lM).
As expected, treatment of cells with ZnCl2 solution
led to a significant increase in Zn concentrations
(ANOVA on ranks, H = 94.125, p\ 0.001, Dunn’s
multiple comparison test: Control vs. ZnCl2
p\ 0.0001). Similarly, ZnGlu, ZnLys/Glu and
ZnLys/Glu/Met significantly increased intracellular
Zn (Fig. 1b) (Control vs. ZnGlu p = 0.0028, Control
vs. ZnLys p = 0.0741; Control vs. ZnLys/Glu p\
0.0001; Control vs. ZnLys/Glu/Met p = 0.0144).
ZnCl2 solution showed stronger effects compared to
ZnMet and ZnLys (ZnCl2 vs. ZnLys p = 0.0138;
ZnCl2 vs. ZnMet p = 0.0004). 120 min after applica-
tion, ZnCl2 solution and all ZnAAs increased intra-
cellular Zn levels (one-way ANOVA, F6.69 = 21.619,
p\ 0.0001, Bonferroni post hoc analysis: Control vs.
ZnCl2, ZnGlu, ZnLys, ZnMet, ZnLys/Glu, ZnLys/
Glu/Met p\ 0.0001), although ZnMet increased
intracellular Zn levels the least (Fig. 1c).
While application of Glu and Lys alone did not alter
intracellular Zn levels compared to untreated controls,
the application of Met alone, in turn, resulted in a
significant increase in intracellular Zn (Fig. 1d),
possibly due to secondary effects (one-way ANOVA,
F = 165.893, p\ 0.001, Bonferroni post hoc
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analysis: Control vs. ZnCl2, Met p\ 0.0001; ZnCl2
vs. Met p\ 0.0001). However, the uptake of free Zn
provided via ZnCl2 solution was not affected by the
presence of Glu, Lys or Met (Fig. 1e) (one-way
ANOVA, F = 53.22, p\ 0.0001, Bonferroni post hoc
analysis: Control vs. ZnCl2, ZnCl2 ? Glu, ZnCl2 ?
Lys, ZnCl2 ? Met, p\ 0.0001).
Next, we investigated whether the uptake of Zn
provided by ZnAAs is inhibited by co-application of
the corresponding AA. In contrast to the application of
ZnCl2, a significant inhibitory effect on the increase in
intracellular Zn levels after application of ZnGlu,
ZnLys, and ZnMet was observed in presence of Glu,
Lys and Met, respectively (Fig. 1f–h) (Fig. 1f: one-
way ANOVA, F = 157, p\ 0.0001, Bonferroni post
hoc analysis: Control vs. ZnGlu p\ 0.0001; Control
vs. ZnGlu ? Glu p = 0.027; Control vs. ZnLys p\
0.0001; Control vs. ZnMet p\ 0.0001; Fig. 1g Lys:
one-way ANOVA, F = 7.841, p\ 0.0001, Bonfer-
roni post hoc analysis: Control vs. ZnLys p = 0.007,
ZnLys vs. ZnLys ? Lys (150) p = 0.003, ZnLys vs.
ZnLys ? Lys (200) p\ 0.0001, ZnLys vs. ZnLys ?
Lys (200) p\ 0.0001; Fig. 1g Glu: one-way
ANOVA, F = 91.44, p\ 0.0001, Bonferroni post
hoc analysis: Control vs. ZnGlu p\ 0.0001, Control
vs. ZnGlu ? Glu (10) p\ 0.0001, Control vs.
ZnGlu ? Glu (50) p\ 0.0001, Control vs. ZnGlu ?
Glu (150) p\ 0.0001, ZnGlu vs. ZnGlu ? Glu (100)
p\ 0.0001, ZnGlu vs. ZnGlu ? Glu (150) p\
0.0001, ZnGlu vs. ZnGlu ? Glu (200) p\ 0.0001).
The inhibition of Zn uptake after application of
ZnAAs via surplus of the corresponding AA follows
a competitive manner as the increase in intracellular
Zn is reduced in a concentration dependent manner by
co-application of the AA (Fig. 1f). Thus, it is possible
that Zn uptake, depending on the source (ZnCl2 or
ZnAAs) is mediated differently in Caco-2 cells. Even
120 min after application of ZnCl2 solution and
ZnAAs, similar mechanisms were detected
(Fig. S2a, b) hinting towards stability of ZnAA
complexes.
Uptake of Zn from ZnAAs is only partially
affected by uptake antagonists
The presence of antagonists of Zn uptake such as
increased amounts of Ca and Cu (Fig. 2a), phytic acid
(PhytAc) (Fig. 2b), and folic acid (FolAc) (Fig. 2c)
did not alter the significant increase in intracellular Zn
levels 30 min after application of ZnAAs in most
cases, but Ca and Cu, as well as phytic acid and folic
acid affected Zn uptake from ZnCl2. The presence of
50 lM CuCl2 and 50 lM CaCl2 significantly reduced
Zn uptake from the ZnCl2 solution (Fig. 2a; ANOVA
on ranks, H = 142.288, p\ 0.0001; Dunn’s multiple
comparisons test: Ctrl vs. ZnCl2, p\ 0.0001; ZnCl2
vs. ZnCl2 ? Ca/Cu, p\ 0.0001). The presence of Ca
and Cu in contrast did not affect the uptake of Zn from
ZnGlu, ZnLys, ZnMet, and ZnLys/Glu/Met (ZnGlu
vs. ZnGlu ? Ca/Cu, p[ 0.999; ZnLys vs. ZnLys ?
Ca/Cu, p[ 0.9999; ZnMet vs. ZnMet ? Ca/Cu, p[
0.999; ZnLys/Glu/Met vs. ZnLys/Glu/Met ? Ca/Cu,
p[ 0.9999). Although, as seen previously, 30 min
after treatment with ZnLys and ZnMet, no significant
increase in intracellular Zn levels was observed, the
presence of Ca and Cu did not affect intracellular Zn
concentrations.
The application of 2.5 mM phytic acid similarly
reduced the significant increase in intracellular Zn
when Zn was added in the form of ZnCl2 (Fig. 2b;
ANOVA on ranks, H = 139.436, p\ 0.001; Dunn’s
bFig. 1 Uptake of Zn from ZnAAs in Caco-2 cells. a Blood
levels of Zn from mice on different diets for 9 weeks. Whole-
blood Zn levels were investigated by AAS in three animals per
group. Animals on a Zn deficient diet (Diet 2) show significantly
reduced Zn levels compared to mice on the control diet (Diet 1).
Mice on the control diet with increased levels of Zn uptake
antagonists (Diet 3) similarly show a significant reduction in
blood-zinc levels. b–h Zinpyr-1 fluorescence intensity of Caco-
2 cells incubated for 30 min with ZnCl2 solution (50 lM) or
ZnAAs delivering an equivalent of 50 lM Zn2?. b ZnCl2
solution, ZnGlu, and ZnLys/Glu and ZnLys/Glu/Met signifi-
cantly increase intracellular Zn. A trend for an increase was seen
after application of ZnLys and ZnMet. ZnCl2 solution increases
intracellular Zn levels significantly more compared to ZnLys
and ZnMet (n = 10 cells per group). c After 120 min, ZnCl2
solution and all ZnAAs lead to a significant increase in
intracellular Zn (n = 10 cells per group). d Application of
Glu and Lys alone do not lead to differences in Zn compared to
untreated controls. The application of Met alone results in a
significant increase in intracellular Zn compared to controls, but
significantly less than seen with ZnCl2 solution (n = 10). e The
significant increase in intracellular Zn levels provided by ZnCl2
solution is not affected by the presence of a surplus of AAs in the
medium. f A significant increase in intracellular Zn after
application of ZnGlu, ZnLys, and ZnMet was not present when
ZnGlu, ZnLys, and ZnMet were applied together with Glu, Lys
and Met, respectively. g The increase in intracellular Zn is
reduced in a concentration dependent manner by co-application
of 10, 50, 100, 150 and 200 lM Lys or Glu, respectively
(n = 10). h Exemplary images for Caco-2 cells stained with
Zinpyr-1 are shown. The bottom row shows the Zinypr1 signal
intensity color-coded
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Fig. 2 Effect of
antagonistic factors on
uptake of Zn from ZnAAs in
Caco-2 cells. Zinpyr-1
fluorescence intensity of
Caco-2 cells. a Application
of Zn uptake antagonists
calcium (provided as CaCl2)
and copper (provided as
CuCl2) together with ZnCl2
solution and ZnAAs. A
significant inhibitory effect
on Zn uptake from ZnCl2
solution is seen. No
significant inhibition of the
uptake of Zn delivered by
ZnGlu, ZnLys, ZnMet, and
ZnLys/Glu/Met was
observed. The uptake of
ZnLys/Glu was significantly
inhibited. b Co-application
of Zn uptake antagonist
phytic acid (PhytAc). Co-
application of ZnCl2 and
phytic acid leads to
significantly less increase in
intracellular Zn levels
compared to cell treated
only with ZnCl2 solution.
No significant antagonistic
effect was observed upon
co-application of phytic acid
and ZnGlu, ZnLys, ZnMet,
ZnLys/Glu, and ZnLys/Glu/
Met. Uptake of ZnLys/Glu/
Met was higher in presence
of phytic acid. Phytic acid
was used in a molar ratio
Zn:PhytAc = 1:50
(n = 10). c Co-application
of Folic acid (FolAc).
Significantly less Zn uptake
via ZnCl2 solution (FolAc
was used with 100 lM
concentration) is observed.
A significant inhibitory
effect on the uptake of
ZnLys, ZnLys/Glu, and
ZnLys/Glu/Met was
observed. Only ZnGlu and
ZnMet are unaffected,
although ZnMet did not
significantly increase
intracellular Zn levels
within 30 min (n.s. not
significant)
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multiple comparisons test: Ctrl vs. ZnCl2, p\0.0001).
In contrast, phytic acid did not significantly impair the
increase caused by ZnGlu and ZnLys/Glu, and uptake
of ZnLys/Glu/Met (ZnGlu vs. ZnGlu ? PhytAc,
p[ 0.9999; ZnLys/Glu vs. ZnLys/Glu ? PhytAc,
p[ 0.9999; ZnLys/Glu/Met vs. ZnLys/Glu/Met ?
PhytAc, p[ 0.9999). Again, ZnLys and ZnMet did
not increase intracellular Zn levels significantly within
30 min of application, but phytic acid also did not
affect Zn levels in these conditions (ZnLys vs.
ZnLys ? PhytAc, p[ 0.9999; ZnMet vs. ZnMet ?
PhytAc, p[ 0.9999).
The presence of folic acid (Fig. 2c) also affected the
significant increase in intracellular Zn delivered by
ZnCl2 solution (Fig. 2c; ANOVA on ranks, H =
134.578, p\ 0.0001; Dunn’s multiple comparisons
test: Ctrl vs. ZnCl2, p\ 0.0001; ZnCl2 vs. ZnCl2 ?
FolAc, p = 0.0482). Again, no significant effect of
FolAc on the increase in intracellular Zn levels caused
by application of ZnGlu was seen (ZnGlu vs.
ZnGlu ? FolAc, p = 0.0537). Folic acid had no
inhibitory effect on Zn in the form of ZnLys, ZnLys/
Glu, and ZnLys/Glu/Met (ZnLys vs. ZnLys ? FolAc,
p[ 0.9999; ZnLys/Glu vs. ZnLys/Glu ? FolAc,
p = 0.0541; ZnLys/Glu/Met vs. ZnLys/Glu/Met ?
FolAc, p[ 0.9999). ZnLys and ZnMet did not
increase intracellular Zn levels significantly within
30 min of application, but folic acid also did not affect
Zn levels significantly after application of ZnMet and
even lead to a slight increase.
Thus, the significant intracellular increase in Zn
levels after application of ZnCl2 solution was impaired
by co-application of all antagonists tested. In contrast,
the significant increase after application of ZnGlu was
unaffected by any of the antagonists. All ZnAAs seem
to be protected from inhibitory effects caused by
phytic acid and folic acid.
Zn from ZnAAs is taken up by AA transporters
in human enterocytes
To further investigate whether ZnAAs are taken up by
AA transporters before dissociation of Zn from the
AA, we performed uptake experiments using entero-
cytes differentiated from human induced pluripotent
stem cells (hiPSC) from a healthy control and a patient
with AE (Fig. 3a–d). The underlying cause of AE in
this patient was identified by genome sequencing and
the results revealed compound heterozygous
mutations 192 ? 19G[A and 599C[T (AA
sequence Pro200Leu) in the hZIP4 gene. Thus, in this
case, Zn uptake is inhibited by a genetic mutation in
the major Zn importer. Differentiated cells from
control and patient were identified as enterocytes by
the expression of the marker proteins Sucrase-Isoma-
ltase (SI) and Peptidase 1 (SLC15A1), and CDX2 and
Villin (Fig. S3a, b). No difference in differentiation
efficacy was found between control and patient.
After differentiating hiPSC to enterocytes (Fig. 3a),
we again exposed the cells from a healthy control and
AE patient to ZnCl2 solution (50 lM) or ZnAAs
delivering an equivalent of 50 lM Zn. Treatment with
the Zn chelators TPEN confirmed the specificity of the
Zinpyr-1 signal. 30 min after treatment, we measured
the intracellular Zn levels by Zinpyr-1 staining
(Fig. 3b–d). The results show that intracellular Zn
levels in enterocytes of the healthy control are
significantly increased after treatment with ZnCl2
solution as observed before in Caco-2 cells (Fig. 3b,
ANOVA on ranks, H = 52.424, p\ 0.0001; Dunn’s
multiple comparisons test: Ctrl vs. ZnCl2,
p = 0.0015). A significant increase in intracellular
Zn was also observed upon treatment with ZnGlu (Ctrl
vs. ZnGlu, p\ 0.0001), while ZnLys, ZnMet and
ZnLys/Glu/Met did not significantly increase intra-
cellular Zn within 30 min after application and the
increase of ZnLys/Glu was statistically visible only as
trend. All measured Zinpyr-1 fluorescence intensities
were significantly different from the TPEN control.
In contrast, enterocytes differentiated from iPSCs
from the AE patient did not show a significant increase
in intracellular Zn after treatment with ZnCl2 solution
(Fig. 3c, d) (Fig. 3c: ANOVA on ranks, H = 45.97,
p\ 0.0001; Dunn’s multiple comparisons test: Ctrl
vs. ZnCl2, p[ 0.9999). Compared to enterocytes
differentiated from iPSCs from the Control, the uptake
of Zn from ZnCl2 solution was significantly less
(Fig. 3d: ZnCl2Control vs. ZnCl2 AE, p\ 0.0001). This
is in line with the expectation that Zn delivered by
ZnCl2 solution is mainly taken up by Zip4, which is
severely functionally impaired in the AE patient. In
contrast, ZnAAs are taken up by enterocytes differ-
entiated from the AE patient and significantly
increased intracellular Zn levels in case of ZnLys/
Glu/Met (Fig. 3c: Ctrl vs. ZnLys/Glu/Met,
p = 0.0071), and ZnGlu tended to increase intracel-
lular Zn levels (Fig. 3c: Ctrl vs. ZnGlu, p = 0.0787).
All measured Zinpyr-1 fluorescence intensities were
Biometals (2017) 30:643–661 649
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significantly different from the TPEN control. In
contrast to uptake by ZnCl2 solution, uptake of ZnAAs
is not significantly different between enterocytes from
Control and the AE patient (Fig. 3d: ZnGluControl vs.
ZnGluAE, p = 0.4665; ZnLysControl vs. ZnLysAE,
p = 0.2688; ZnMetControl vs. ZnMetAE, p = 0.8083;
650 Biometals (2017) 30:643–661
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ZnLys/GluControl vs. ZnLys/GluAE, p = 0.8772) with
exception of ZnLys/Glu/Met which significantly
increased intracellular Zn level in cells from the AE
patient 30 min after application (Fig. 3d: ZnLys/Glu/
MetControl vs. ZnLys/Glu/MetAE, p = 0.0055).
Enterocytes differentiated from control iPSC also
display similar uptake of compounds and ZnCl2
solution compared to Caco-2 cells in presence of
uptake antagonists (Fig. S3c). 30 min after treatment
with ZnCl2 solution or ZnGlu, a significant increase in
intracellular Zinpyr-1 fluorescence was detected
(ANOVA on ranks, H = 36.342, p\ 0.0001; Dunn’s
multiple comparisons test: Ctrl vs. ZnCl2, p\ 0.0001;
Ctrl vs. ZnGlu, p = 0.0103). While uptake of Zn from
ZnCl2 solution was significantly impaired by Ca, Cu,
and phytic acid and tended to be impaired by folic acid
(ANOVA on ranks, H = 36.8, p\ 0.0001; Dunn’s
multiple comparisons test: ZnCl2 vs. ZnCl2 ? Ca/Cu,
p\ 0.0001; ZnCl2 vs. ZnCl2 ? PhytAc, p\ 0.0001;
ZnCl2 vs. ZnCl2 ? FolAc, p = 0.0804), uptake of
ZnGlu was not significantly affected by presence of
antagonists (ANOVA on ranks, H = 1.515,
p = 0.6787). Although application of ZnLys and
ZnMet did not result in significant increases in intra-
cellular Zinpyr-1 fluorescence within 30 min, a signif-
icant alteration of Zn levels was only observed for
ZnLys in presence of FolAc (ANOVA on ranks,
H = 28.51, p\0.0001; Dunn’s multiple comparisons
test: ZnLys vs. ZnLys ? FolAc, p = 0.0003) and for
ZnMet in presence of Ca/Cu (ANOVA on ranks,
H = 14.68, p\0.0001; Dunn’s multiple comparisons
test: ZnLys vs. ZnLys ? FolAc, p\ 0.0001).
Zn from ZnAA is absorbed in similar quantity
compared to free Zn
Therefore, next, to study not only uptake but actual
absorption, we used a transwell system (Fig. 3e).
Enterocytes differentiated from human iPS cells were
plated on the filter of a transwell insert and grown until
they were 100% confluent (Fig. 3e). To control for
gaps, FITC Dextran was applied to some wells and the
increase in fluorescence in the basal medium con-
trolled (Fig. S4). ZnCl2 solution or ZnAAs were
applied to the supernatant. After 120 min, the super-
natant and the basal medium (Fig. 3e) were removed
and the transport of Zn through the layer of cells was
determined by measuring the Zn concentration of
supernatant and basal medium (Fig. 3g, h). The results
show that 120 min after treatment, the intracellular Zn
concentration was significantly elevated after incuba-
tion with ZnCl2 solution or ZnAAs (Fig. 3f) (one-way
ANOVA, F4.49 = 19.316, p\ 0.0001, Bonferroni
post hoc analysis: Control vs. ZnCl2, ZnGlu, ZnLys,
ZnMet p\ 0.0001). In enterocytes differentiated from
iPSC from the Control, incubation with ZnCl2 solution
(50 lM Zn) or ZnAAs (50 lM Zn) resulted in a
significant increase of Zn concentration in the basal
medium compared to untreated control cells (one-way
ANOVA, F = 53.716, p\ 0.0001, Bonferroni post
hoc analysis: Control vs. ZnCl2, p\ 0.0001, Control
vs. ZnGlu, p = 0.0006; Control vs. ZnLys, p =
0.0238; Control vs. ZnMet p = 0.0029). However,
the absorption of ZnGlu was significantly less
bFig. 3 Zn uptake in human enterocytes differentiated from
healthy controls and patients with Acrodermatitis enteropath-
ica. a Overview of the protocol for generation of enterocytes
from hIPSC of a healthy control and AE patient. b, c Enterocytes
were exposed to ZnCl2 solution (50 lM) or ZnAAs delivering an
equivalent of 50 lM Zn for 30 min. Treatment with the Zn
chelator TPEN confirmed the specificity of the Zinpyr-1 signal.
b Intracellular Zn levels in enterocytes of the healthy control are
significantly increased after treatment with ZnCl2 solution and
ZnGlu. ZnLys, ZnMet, ZnLys/Glu and ZnLys/Glu/Met did not
significantly increase intracellular Zn within 30 min after
application. c Intracellular Zn levels in enterocytes of the AE
patient did not show a significant increase after treatment with
ZnCl2. Application of ZnLys/Glu/Met (significant) and ZnGlu
(as trend) leads to an increase in intracellular Zn levels. d A
significant difference in uptake of Zn from ZnCl2 solution
between enterocytes from Control and the AE patient was
detected. Uptake of ZnAAs is not significantly lower in
enterocytes from the AE patient compared to the Control.
Uptake from ZnLys/Glu/Met was significantly higher in cells
from the AE patient. e Enterocytes differentiated from hIPSC
were plated on the filter of a transwell system. ZnCl2 solution
or ZnAAs were applied to the supernatant. After 120 min, the
supernatant and the basal medium were removed. Cells on the
filter were grown until they were 100% confluent and are
visualized by DAPI staining of cell nuclei. f After incubation
with ZnCl2 or ZnAAs, a significant increase in Zinpyr-1 staining
in cells (n = 10) was detected. g Left: Using cells from the
Control, all treatments resulted in a significant increase of Zn
concentration in the basal medium (measured by AAS). The
absorption of ZnGlu was significantly less compared to ZnCl2
solution and ZnMet. Right: Using cells from the AE patient,
incubation with ZnCl2 solution did not result in a significant
increase of Zn concentration in the basal medium compared to
untreated control cells, while application of all ZnAAs
significantly increase the Zn concentration in the basal medium.
The absorption of ZnLys was significantly higher compared to
ZnCl2 solution, ZnGlu and ZnMet. h Comparing the healthy
control and the AE patent, significant differences were detected
in the absorption of Zn from ZnCl2 solution and after application
of ZnGlu and ZnMet
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compared to ZnCl2 solution and ZnMet (ZnCl2 vs.
ZnGlu, p\ 0.0001; ZnGlu vs. ZnMet p = 0.0085). In
enterocytes differentiated from iPSC from the AE
patient, incubation with ZnCl2 solution (50lMZn) did
not result in a significant increase of Zn concentration
in the basal medium compared to untreated control
cells (one-way ANOVA, F = 30.691, p\ 0.0001,
Bonferroni post hoc analysis: Control vs. ZnCl2,
p = 0.0544). In contrast, application of ZnAAs (50
lM Zn) resulted in a significant increase of Zn
concentration in the basal medium (Control vs. ZnGlu,
p = 0.0008; Control vs. ZnLys, p\ 0.0001; Control
vs. ZnMet p\ 0.0001). The absorption of ZnLys was
significantly higher compared to ZnCl2 solution,
ZnGlu and ZnMet (ZnCl2 vs. ZnLys, p = 0.0259;
ZnGlu vs. ZnLys p = 0.0103; ZnMet vs. ZnLys
p = 0.0008) (Fig. 3g).
Thus, while uptake of Zn into cells is faster byZnCl2
compared to most ZnAAs after 30 min, uptake is
similar after 120 min, which is reflected in similar
levels of absorption after 120 min with slight advan-
tage for ZnLys. Comparing enterocytes from the
healthy control and the AE patent (Fig. 3h), significant
differences can be detected (one-way ANOVA,
F = 42.013, p\ 0.0001). Post hoc analyses reveal a
difference in absorption of Zn from ZnCl2 solution
(ZnCl2 Control vs. ZnCl2 AE, p = 0.0047) that was
significantly less in cells from the AE patient. Further
differences were detected after application of ZnGlu,
whichwas significantly better absorbed in cell from the
AE patient (ZnGluControl vs. ZnGluAE, p = 0.0073),
and ZnMet (ZnMetControl vs. ZnMetAE, p = 0.0373)
that showed less absorption in cell from the AE patient
compared to cells from the healthy control.
Uptake of Zn by ZnAAs does not affect Zn and AA
importer expression or localization
Homeostasis of intracellular Zn concentrations, under
physiological conditions, is maintained in cells by
specific regulatory pathways. An increase in intracellu-
lar Zn, for example, leads to Zn binding to the metal
transcription factor-1 (MTF1) that translocates into the
nucleus in a Zn-bound state. There, MTF-1 binds to
specific sequences, so called metal response elements
(MREs) in the promoter region of target genes, among
themZnT1. This increases the mRNA expression levels
of ZnT1 and subsequently protein numbers. Given that
ZnT1 is a Zn exporter, this increase leads to a reduction
of intracellular Zn levels maintaining initial Zn home-
ostasis. We therefore quantified the expression levels
and subcellular localization of selected candidate genes
such as ZIP2, ZIP4 and ZnT1 on mRNA and protein
level. Both, ZIP2 and ZIP4 have been shown to regulate
Zn uptake into enterocytes. The level of mRNA
abundance and subcellular localization of ZIP4 were
reported to change in response to Zn levels (Dufner-
Beattie et al. 2003).
Alternatively, Zn complexes with AAs might
bypass this system and might be taken up as well as
exported, in part, via AA transporters. Thus, we
additionally analyzed selected candidate genes such as
cFig. 4 Physiological responses to Zn uptake in Caco-2 cells.
a Quantification of gene expression levels using qRT-PCR. The
average mRNA expression (Dct value) normalized to HMBS is
shown compared to untreated (control) cells. Cells were treated
with ZnCl2 (50 lM), ZnGlu (delivering an equivalent of 50 lM),
ZnGlu and Glu (200 lM), or Glu (200 lM) alone. No significant
changes were detected for the Zn transporters ZIP2 and ZnT1.
Expression of ZnT1 shows high dynamics and a clear trend
towards an up-regulation. ZIP4 levels are significantly different
between cells treated with Glu compared to ZnCl2 and ZnGlu
treatment. Amino acid transporters (SLC1A1, SLC7A6, SLC7A8
and SLC6A14) are unaffected by the treatments. SLC36A1 is
significantly up-regulated after treatment with ZnGlu ? Glu and
shows significantly different expression in response to ZnGlu vs.
Glu alone. SLC36A2 shows significantly increased expression
after treatment with ZnCl2 and ZnGlu (as a trend) (n = 3 per
condition). b–d Expression of Zip2, Zip4 and ZnT1 on protein
level using Western Blot. The integrated density of 3 immunore-
active bands per condition was measured. b 30 min after
application of ZnCl2 and ZnGlu, no significant regulation can be
detected on protein level. c After 120 min, no alterations are
detected regarding total Zip2 and Zip4 levels. A significant
decrease in total cell ZnT1 concentration is observed after
treatment with ZnCl2 or ZnGlu. d Exemplary western blot bands
for the evaluation of Zip2, Zip4, ZnT1 and SLC36A1, SLC36A2,
and SLC6A14 protein levels after 120 min. e The AA transporter
SLC6A14 shows an up-regulation on total protein level after
120 min only after treatment with ZnGlu. No significant
difference is detected for SLC36A1 and SLC36A2. f Immunocy-
tochemistry was performed on Caco-2 cells (n = 10 per
condition) and the fluorescence intensity of SLC6A14, Zip2,
Zip4 and ZnT1 signals measured 120 min after treatment. A
significant decrease of cell surface SLC6A14 signals after
treatment with ZnLys but not the other ZnAAs is detected.
Application of Lys alone does not elicit these alterations. Glu
treatment slightly enhances SLC6A14 surface localization. For
Zip2, no significant differences are detected in cell surface
location, although a trend towards a reduction after ZnCl2
treatment and treatment with ZnAAs is seen (significant for
ZnCl2 vs. Glu). No significant differences are detected in cell
surface location of Zip4. The levels of ZnT1 at the cell surface
were significantly increased after treatment with both ZnCl2
solution andZnAAs, despite the decrease in total protein levels (c)
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AA transporters SLC1A1, SLC7A6, SLC7A8,
SLC6A14, SLC36A1 and SLC36A2 on mRNA and
protein level (Fig. 4). SLC7A6, SLC7A8, SLC36A1
and SLC3A2 are sodium-independent AA transporters
expressed in enterocytes and Caco-2 cells, mediating
the uptake of a wide range of AAs including Met, Lys
and Glu. SLC1A1 and SLC6A14 are sodium-depen-
dent AA transporters.
Our results reveal no significant changes of Zn
transporters compared to controls in response to ZnCl2
solution or ZnAAs, although expression levels of ZnT1
are highly increased after administration of ZnCl2
(Fig. 4a). The AA transporters (SLC1A1, SLC7A6,
SLC7A8 and SLC6A14) are unaffected by any of the
treatments (Fig. 4a: one-way ANOVA, p[ 0.05).
However, SLC36A2 is significantly up-regulated on
mRNA level after treatment with ZnCl2 solution (one-
way ANOVA, F4.14 = 7.608, p = 0.004, Bonferroni
post hoc analysis: Control vs. ZnCl2 p = 0.021).
To test whether differences might occur on protein
level rather than in gene expression, we quantified the
expression of Zip2, Zip4 and ZnT1 usingWestern Blot
analysis (Fig. 4b–d). 30 min after application of ZnCl2
and ZnGlu, no significant regulation can be detected on
protein level (Fig. 4b, one-way ANOVA, ZIP2:
F2.8 = 0.2954 p = 0.7545; ZIP4: F2.8 = 0.4382
p = 0.6643; ZnT1: F2.8 = 0.1858 p = 0.8351). After
120 min, no changes were detected in Zip2 (one-way
ANOVA, F2.8 = 0.754 p = 0.51) and Zip4 (F2.8 =
2.201 p = 0.192), and a down-regulation of total
cellular ZnT1 protein was found for both treatment
groups (one-way ANOVA, F2.8 = 19.088 p = 0.003;
Bonferroni post hoc analysis: Control vs. ZnCl2
p = 0.004; Control vs. ZnGlu p = 0.007) (Fig. 4c,
d). The AA transporter SLC6A14 showed a significant
increase only in response to ZnGlu and not to ZnCl2
(Fig. 4d, e) (one-way ANOVA, F2.8 = 7.102 p =
0.026; Bonferroni post hoc analysis: Control vs. ZnCl2
p = 0.584; Control vs. ZnGlu p = 0.029).
In addition to alterations in expression levels, the
localization of transporters at the membrane might
change. Thus, we additionally performed immunocyto-
chemistry on treated Caco-2 cells and evaluated
immuno-reactive signals at the cell surface of Zip2,
Zip4, ZnT1 and SLC6A14 (Fig. 4f). The results show
that a significant change occurs in SLC6A14 signals
(one-way ANOVA, F7.79 = 46.604 p\ 0.0001). Bon-
ferroni post hoc analysis reveals that the SLC6A14
fluorescence intensity at the membrane after treatment
with ZnLys significantly decreases (Control vs. ZnLys
p\ 0.0001). Interestingly, treatment with Lys alone,
but also treatment with ZnCl2 solution did not induce
this change (Control vs. Glu p = 0.055; Control vs. Lys
p = 0. 204; Control vs. ZnCl2 p = 0. 077). Zip2
membrane expression was not altered between the
treatment groups and control, but a significant differ-
ence was found between treatment with ZnCl2 solution
andGlu (one-wayANOVA, F7.79 = 20.720 p = 0.003;
Bonferroni post hoc analysis: ZnCl2 vs. Glu p = 0.002).
Membrane Zip4 levels were significantly altered
(ANOVA on ranks, H = 21.52 p = 0.0031; Dunn’s
post hoc test: ZnCl2 vs. Lys p = 0.034). However, no
significant alterations after application of ZnCl2 or
ZnAAs compared to Control were observed. ZnT1
levels at the plasma membrane were significantly
increased after both treatment with ZnCl2 solution and
ZnGlu, ZnLys and ZnMet (one-way ANOVA,
F7.79 = 62.766 p\ 0.0001; Bonferroni post hoc anal-
ysis: Control vs. ZnCl2 p\ 0.0001; Control vs. ZnGlu,
ZnMet and ZnLys p\ 0.0001).
Thus, taken together, application of ZnAAs does not
elicit a homeostatic down-regulation of Zn importers
on mRNA or protein level. However, treatment of
Caco-2 cells with ZnAAs leads to an up-regulation of
cell surface ZnT1 leading to Zn export. In the
gastrointestinal tract, this export would be directed to
the blood circulation. In addition, application of
ZnAAs also does not lead to major compensatory
regulations of AA transporters. Thus, Zn uptake from
ZnAAs over time is not reduced, possibly bypassing
homeostaticmechanisms that diminish Zn uptake upon
chronic exposure to high Zn levels.
Discussion
Zn is absorbed from our dietary sources and/or
supplements in the proximal small intestine, either
the distal duodenum or proximal jejunum (Krebs et al.
1998; Lee et al. 1989) and released in the blood stream
via transporters. However, various agents present in
the diet can decrease Zn absorption (Cousins 2010).
To prove this in an in vivo situation, we used mice and
fed them a special diet containing either adequate Zn
concentrations, inadequate Zn concentrations, or ade-
quate Zn concentrations in presence of increased
levels of Zn uptake antagonists such as phytic acid,
Ca/Fe, and folic acid. Control animals displayed
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normal Zn levels in whole-blood in a magnitude as
reported before (Grabrucker et al. 2016). As expected
mice on a Zn deficient diet showed a significant
reduction of Zn levels in the blood after 9 weeks. As
whole-blood Zn was investigated, this reduction does
not only reflect decreased Zn levels of a fast
exchanging pool of plasma Zn, but indicated a
systemic Zn deficiency affecting intracellular Zn
levels in several tissues. An important finding is that
a similar Zn deficiency is produced in animals fed the
control diet with adequate Zn supply but with
increased levels of Zn uptake antagonists. In addition,
genetic mutations in Zn transporters such as Zip4 in
AE, may significantly lower Zn uptake.
Today, suboptimal Zn intake that might also lead to
secondary nutritional problems is present not only in
many developing countries but also in industrial
nations (Lo¨nnerdal 2000). Supplementation with Zn
has, among others, effects on linear growth (Brown
et al. 1998), the immune system (Shankar and Prasad
1998), and pregnancy outcome (Goldenberg et al.
1995). Intriguingly, among individuals with Autism
Spectrum Disorders (ASD), the incidence rate of Zn
deficiency has been reported to be significantly higher
compared to age matched healthy control subjects
(Pfaender and Grabrucker 2014). In the light of these
findings, maintaining adequate Zn status during preg-
nancy and early development might be a promising
approach to prevent cognitive and neurobehavioral
deficits later in life. However, in most cases and
especially in industrialized nations, the cause of
suboptimal Zn absorption is not an inadequate dietary
intake of Zn, but the presence of antagonists in the
diet. Therefore, it is necessary to investigate the
efficacy of different Zn compounds in their ability to
deliver Zn despite the presence of inhibitory factors or
abnormalities in Zn transporters.
Here, we investigated the route of absorption of
ZnAA compounds. Our results show that Zn delivered
by ZnAAs is taken up into cells in a similar magnitude
as Zn delivered as free Zn (by Zn salts) after two
hours, although uptake is slower. Similar results were
reported before using CuAAs, where the uptake of
CuAAs was lower compared to inorganic Cu solution,
but the amino acid complex forms facilitated Cu
absorption in Caco-2 cells. The enhanced absorption
of CuAA appeared to be mediated by amino acid
transporters (Gao et al. 2014). Bath application of 50
lMZn led to an approx. 3 fold increase in intracellular
Zn levels after two hours. In this study, changes in Zn
levels induced by ZnCl2 or ZnAA supplementation are
shown relative to controls. Measuring absolute Zn
concentrations using Zinpyr-1 fluorescence signal
intensities is difficult to perform, as several compo-
nents, such as buffering proteins in the medium of
cells that contains fetal bovine serum (FBS), introduce
variables that may lead to a non-linear realtionship of
Zn and fluorescence intensity. Further, quantitative
measurements of Zn concentrations using fluo-
rophores such as Zinpyr-1 are difficult, as not only
free but also protein bound Zn is detected to some
extent, and comparisons of relative values between
ZnCl2 and ZnAAs may be more meaningful.
It was shown that with increasing amounts of Zn in
a diet, the amount of Zn absorbed decreases (Lo¨nner-
dal 2000; Sandstro¨m and Cederblad 1980). This
reduction in fractional absorption of zinc at higher
doses most likely is due to the saturation of Zn
transporters. For example, in humans after intestinal
perfusion with solutions with increasing concentration
of Zn, first a linear increase in Zn absorption was
observed. However, at higher concentrations, the rates
leveled out (Lee et al. 1989).
Intriguingly, in cells from an AE patient, no
impairment in the absorption of ZnAAs was seen in
contrast to ZnCl2. We could show that, at least in part,
ZnAA are taken up via AA transporters. Thus, uptake
of Zn from ZnAAs is not impaired in cells from an AE
patient with mutated ZIP4 gene, but inhibited by
increased levels of AA competing with ZnAAs for AA
transporters. Although uptake may also be mediated
by other transporters such as DMT-1, it is unlikely that
DMT-1 transports ZnAAs and is inhibited by AAs.
Further, the structure of the ZnAAs makes it unlikely
that they function as ionophores. AAs generally show
poor membrane permeability (Chakrabarti 1994) and
ZnAAs are structurally not drastically different from
the corresponding AAs.
While we could not detect major changes in mRNA
and total protein levels of zinc importers Zip2 and
Zip4 after treatment with ZnAAs, similar to exposure
to ZnCl2 solution, levels of membrane bound ZnT1
exporters were significantly increased as homeostatic
control mechanism of cells to reduce increased
intracellular Zn levels (Cousins 2010). However, we
could not detect a reduction of AA transporters in
response to ZnAA. Given that Zn importer and AA
importer levels are unaffected by exposure to
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increased levels of ZnAA, it is likely that the uptake of
Zn by ZnAA is a process that will not be compensated
by homeostatic regulation of AA transports and given
the abundance of AA transporters will not be easily
saturated. It might even be possible to increase Zn
levels beyond physiological concentrations using
ZnAAs.
Zn is likely to predominantly be transported as
‘‘free’’ Zn via a saturable, specific transport mecha-
nism such as Zn importers from the ZIP family
(Sandstro¨m 1992). This, however, makes the ‘‘free’’
Zn susceptible for competition with other metals and
dietary ligands that may considerably lower the
concentration of ‘‘free’’ Zn. Zn delivery by ZnAA, in
particular ZnGlu, which is among the most
stable ZnAAs tested, is less affected by uptake
inhibitors compared to Zn delivery by ‘‘free’’ Zn from
ZnCl2 solution. Especially high levels of Ca and Cu
were not able to inhibit uptake of Zn via ZnGlu and
ZnLys/Glu/Met in vitro.
Although it is unlikely that the level of Cu in the
diet or in a supplement would reach the levels used in
this study in vivo, an interaction of Ca and Cu has been
described in experimental animals, albeit at very high
ratios. Most likely, Cu and Zn compete on cellular
level for binding partners necessary for absorption
such as metallothioneins or metal transporters. How-
ever, the Cu/Zn interaction is at present poorly
understood. The data obtained through our studies
argues for a possible competition already at the level
of cellular uptake as the increase of intracellular Zn by
application of ‘‘free’’ Zn was significantly decreased
in presence of high Ca and Cu concentrations, but
uptake of ZnGlu and other ZnAAs seemed unaffected.
Delivery of Zn by ZnGlu, ZnLys/Glu and ZnLys/
Glu/Met was also not affected by the presence of high
levels of phytic acid. Animal experiments have shown
that the absorption of Zn is inversely correlated to the
concentration of phytic acid in the diet (Lo¨nnerdal
et al. 1988). The phosphate groups in phytic acid form
insoluble complexes with Zn, and phytate-bound Zn
will be excreted in the feces, thereby causing an
inhibitory effect on Zn absorption (O’Dell 1969;
Vohra and Kratzer 1964). Phytate is present in staple
foods like cereals, corn and rice, and the removal or
reduction of phytate by methods such as phytase
treatment or fermentation markedly improves Zn
absorption. In case of ZnAA, it is possible that Zn
will not be as accessible as ‘‘free’’ Zn and thus less
complex formation with phytic acid will occur.
Folic acid has been reported to increase fecal Zn
excretion, which might indicate an inhibitory effect on
Zn absorption (Ghishan et al. 1986; Simmer et al.
1987; Krebs 2000). Intriguingly, pregnant women are
encouraged to supplement folic acid in their diet, as a
lack of folic acid has been associated with birth defects
such as spina bifida. However, recent studies suggest
that excessive amounts of folate might increase the
risk for the occurrence of ASD (Raghavan et al. 2016).
One might speculate that the underlying patho-mech-
anism could be a prenatal Zn deficiency that has been
shown to induce autism-like behavior in mice
(Grabrucker et al. 2014, 2016; Grabrucker 2014).
Uptake of most ZnAAs tested was affected by the
presence of folic acid, which might argue for a
possible indirect interaction of folic acid with pro-
cesses such as Zn homeostasis. However, we observed
no significant influence of increased levels of folic
acid on Zn delivery by ZnGlu. ZnGlu therefore might
be an interesting compound if Zn should be supple-
mented together with folic acid.
Our result supports the need for a careful assess-
ment of bioavailability of Zn in the human diet, as
dietary habits may change and required daily dosages
might need to be adjusted to prevent Zn deficiencies.
Especially during pregnancy, consumption of supple-
ments containing high folic acid and Ca and Fe
concentrations may create the need for higher Zn
intake to ensure maintenance of physiological Zn
levels and possibly reduce the risk for neurodevelop-
mental disorders in the offspring.
Taken together, we conclude that Zn can be
enriched in cell systems and animals using ZnAAs.
The uptake of ZnAAs might be slower, however,
uptake and absorption reaches a similar quantity
compared to ‘‘free’’ Zn over time. Most importantly,
the advantage of ZnAAs lies in their ability to utilize
less saturable pathways for uptake and in the feature
that ZnAA compounds are protected from antagonistic
factors in the diet to some extent. Therefore, they
might be a superior supplement in cases of genetic
defects in pathways responsible for uptake of ‘‘free’’
Zn, such as mutations in Zn transporters as seen in AE,
or in case of diets with high concentrations of uptake
antagonists and in combination with other supple-
ments delivering Cu or folic acid for example.
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Materials and methods
Materials, chemicals and reagents
Zinpyr-1 was purchased from Sigma Aldrich. Primary
antibodies were purchased from Synaptic Systems
(ZnT1), Abcam (Zip2 (1:1000), Zip4 (1:125),
SLC6A14), Acris (Zip4 (1:200)), Thermo Fisher
(SLC36A1 (1:500)), Invitrogen (SLC36A2 (1:500)),
and Sigma Aldrich (b-Actin, (1:1000)). Secondary
HRP conjugated antibodies were purchased from
Dako (anti-rabbit 1:1000) and Dianova (anti-mouse
1:10,000). DMEM, DMEM/F12 GlutaMAX, RPMI
advanced, Non-essential amino acids (NEAA), B27,
N2, FBS and Antibiotic–Antimycotic were acquired
from Gibco. Unless otherwise indicated, all other
chemicals were of analytical grade and obtained from
Sigma-Aldrich.
ZnAAs—Zinc amino acid complexes (ZnAAs)
(Fig. S1a) were obtained from Zinpro Corporation
(Eden Prairie, MN USA). ZnGlu, ZnMet, ZnLys and,
to utilize as many amino acid transporters as possible
(cationic, anionic and hydrophobic transporters),
combinations were used. We chose lysine since it
has an active transporter. It also has a stability constant
greater than that of methionine in metal complexes
(Furia 1975). The complex with Zn is between the
carboxyl group and the alpha nitrogen. The side group
may increase the stability but is not needed for
binding. ZnAA structures with the complex between
the acid and amine groups forming a 5 membered ring.
The complexes are known to survive the stomach acid
and get absorbed in animals based on the results of
several studies where animals were supplemented with
ZnAA or ZnAA in addition to inorganic Zn and
significant differences were detected compared to
supplementation with Zn salt (Nayeri et al. 2014).
However, the stability of of ZnAAs in low stomach pH
has not yet been directly determined.
ZnAA compounds were obtained as powder and
solutions were freshly prepared for each experiment.
The calculated MW for a ZnAA was taken into
account to prepare the solutions.
Caco-2 colorectal adenocarcinoma cell line
Caco-2 cells (American Type Culture Collection
(ATCC HTB-37TM)) were used between passage
20 and 43. The cells were maintained in 175-cm2
flasks in Dulbecco’s minimal essential medium
(DMEM) supplemented with 10% fetal bovine serum,
1% non-essential amino acids (NEAA), 1% L-Glu-
tamine, and 1% Antibiotic–Antimycotic 1009 (Invit-
rogen). Cells were grown to 100% confluence on a 24
well plate or 10 cm petri dish. Treatment was
performed on DIV 10, as Caco-2 cells differentiate
spontaneously in culture to mature intestinal entero-
cytes within 21d, and we detected expression of Zn
and AA transporters and enterocyte like morphology
after 10 d in culture with no change until DIV 21,
except for a decrease of ZIP4 in Caco-2 cells older
than 10 DIV (Fig. S5a–c).
Animals
Female C57BL/6JRj mice were purchased from
Janvier labs. Mice (8 weeks of age) were habituated
for two weeks (receiving the same diet). Subsequently,
mice received a special laboratory diet (ssniff GmbH,
Germany; Supplementary data 1) with access to food
and water ad libitum for 9 weeks. Animals on Zn
deficient diet received distilled water; all other groups
had access to tap water. Three animals per group were
analyzed. All animal experiments were performed in
compliance with the guidelines for the welfare of
experimental animals issued by the Federal Govern-
ment of Germany and by the local ethics committee
(Ulm University) ID Number: 1257.
Generation of iPSC from a patient
with Acrodermatitis enteropathica
After informed consent, keratinocytes were obtained
from plucked human hair and plated on matrigel
diluted 1:10 in EpiLife (Gibco). Plated hair was
cultivated in MEF conditioned medium supplemented
with 10 ng/ml FGF2 (Cell Guidance Systems), 20 ng/
ml Ascorbic Acid (Sigma-Aldrich) and 10 lM Rho-
associated kinase (ROCK) inhibitor (Ascent Scien-
tific) and medium changed to Epilife supplemented
with 10 lM ROCK inhibitor after keratinocyte out-
growth. IPSC lines were reprogrammed from human
hair keratinocytes via lentiviral transduction as previ-
ously described with a multicistronic vector published
by Warlich et al. (2011) (Linta et al. 2012). iPSC were
cultured in mTeSR1 medium (Stemcell Technologies)
on matrigel (BD Biosciences) coated 6-well plates at
37 C, 5% CO2 and 5% O2.
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Stem cell-differentiation into enterocyte-like cells
The differentiation was performed using a protocol by
Iwao et al. (2014). Human induced pluripotent stem
cell lines between passages 15 and 20 were grown to
70% confluence in mTeSR1 stem cell medium.
Differentiation to definite endoderm was initiated by
changing the medium to RPMI advanced supple-
mented with 2 mMGlutaMAX, 0.5% FBS, 100 ng/ml
Activin A (Cell Guidance Systems) and 1% Antibi-
otic–Antimycotic. After 48 h, cells were grown in
RPMI advanced supplemented with 2 mM Glu-
taMAX, 2% FBS, 100 ng/ml Activin A and 1%
Antibiotic–Antimycotic for 24 h. The medium was
changed to DMEM/F12 GlutaMAX containing 2%
FBS, 250 ng/ml FGF-2 (Cell Guidance Systems) and
1% Antibiotic–Antimycotic for 96 h. Subsequently
cells were treated with 10 lM ROCK Inhibitor
(Ascent Scientific) for 1 h, detached with TrypLE
and plated onMatrigel coated 12-well plates. The cells
were cultured in DMEM/F12 ? GlutaMAX, 2% FBS,
1% NEAA, 2% B27, 1% N2, 20 ng/ml EGF (Invitro-
gen), and 1% Antibiotic–Antimycotic. B27 and N2
were purchased from GIBCO. Medium was changed
every 3 days. The cells were used after 3 weeks in
culture (d21). Cells were grown to 100% confluence
on a 24 well plate or a 12 well Corning Costar
Transwell plate with 3 lm pore Polyester (PET)
membrane insert and also used at d21. Confluency and
leakage through gaps in the cell layer we controlled by
microscopy and application of FITC Dextran, respec-
tively. FITC Dextran fluorescence was determined
using a fluorimeter (Jenway 62 series) and UV table.
Immunocytochemistry
After fixation in 4% Paraformaldehyde/4% Sucrose at
room temperature for 15 min, the cells were washed
with PBS and permeabilized with 0.2% Triton X-100
in PBS for 5 min twice. Subsequently, blocking
solution (BS; 10% FBS in PBS) was applied at room
temperature for 1 h. Cells were incubated with the
primary antibodies at 4 C over night. After washing
39 with PBS, the cells were incubated with Alexa
Fluor conjugated secondary antibody diluted 1:1000 in
BS at room temperature for 1 h. After washing 29
with PBS and 19 with sterile Millipore water, cells
were mounted with ProLong Gold antifade reagent
with DAPI. Fluorescence images were obtained an
upright Axioscope microscope equipped with a Zeiss
CCD camera (16 bits; 1280 9 1024 ppi) using
Axiovision software (Zeiss) and analyses of integrated
densities was performed with ImageJ 1.50 g.
Measurement of trace metal concentrations
For fluorescent Zn-staining of cultured cells, growth
medium was discarded and the cells were washed with
PBS. Coverslips were incubated with a solution of 50
lM Zinpyr-1 (Burdette et al. 2001) in PBS for 1 h at
RT. The mean intracellular Zn concentration per cell
was determined by Zinpyr-1 fluorescence intensity.
Images were obtained using an Axioscope microscope
and evaluated with ImageJ 1.50 g. The Zn-concentra-
tion of solutions and blood was measured by flame
atomic absorption spectrometry (AAS) at the Depart-
ment of Clinical Chemistry (ZE klinische Chemie) of
the University Hospital Ulm using a PinAAcle 900T
from Perkin Elmer and in the workgroup of Prof. Rink,
Institute of Immunology, University Hospital Aachen
using a Perkin Elmer AAnalyst 800 instrument. All
reagents for atomic absorption were of appropriate
quality for trace element analysis (TraceSelect,
Fluka). Samples were diluted in ultrapure water
containing 0.2% (v/v) HNO3 and quantified with a
standard curve between 0 and 1 mg l-1 zinc in 0.2%
(v/v) HNO3, measuring the absorption at 213.9 nm
(slit 0.7 nm). A reference samples spiked with defined
concentrations of Zn were routinely analyzed to
ensure reliable quantification. Whole blood from mice
was collected in Lithium-Heparin Microvettes (Sarst-
edt) and stored at -20 C until further analysis.
Cell lysis and RNA preparation
Cells were harvested and resuspended in 600 ll RIPA
buffer, and kept for 30 min on ice. Lysate was cleared
from debris by centrifugation (14,000 rpm, 15 min)
and stored at -80 C with Protease Inhibitor. Total
RNA was isolated from cell-pellets resuspended in
RLT buffer with the RNeasy Mini Kit according to the
manufacturer’s protocol. All of the optional purifica-
tion steps were performed and RNA eluted with sterile
RNAse free water.
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qRT-PCR
First strand synthesis and quantitative real-time-PCR
amplification were performed in a one-step, single-
tube format using the QuantiFastTM SYBR Green RT-
PCR kit from Qiagen according to the manufacturer’s
protocol in a total volume of 20 ll and the Qiagen
QuantiTect Primer Assays: Hs_CDX2_1_SG (QT000
37807), Hs_VIL1_1_SG (QT00095837), Hs_SLC39A
4_va.1_SG (QT01022637), Hs_HMBS_1_SG (QT00
014462), Hs_SLC39A2_1_SG (QT00213388), Hs_SL
C30A1_1_SG (QT00096320), Hs_SLC1A1_1_SG
(QT00065303), Hs_SLC7A6_1_SG (QT00052248),
Hs_SLC7A8_1_SG (QT00006384), Hs_SLC36
A1_1_SG (QT00029281), Hs_SLC36A2_1_SG (QT0
0070875), Hs_SLC6A14_1_SG (QT00087542). The
qRT-PCR was set up with the following program
(Reverse Transcription, 50 C, 100, 1 cycle; Denatu-
ration, 95 C, 50, 1 cycle; [Denaturation, 95 C, 1000,
combined annealing/extension, 60 C, 3000], 40
cycles; Melting curve analysis, 60–95 C, 9000 (first
step, elevation of 1 C/step), 500 (following steps);
Cooling, 4 C). Thermal cycling and fluorescent
detection were performed using the Rotor-Gene Q
real-time PCR machine (model 2-Plex HRM) (Qia-
gen). The SYBR Green I reporter dye signal was
measured. Resulting data were analyzed using the
HMBS gene as an internal standard to normalize
transcript levels. Cycle threshold (ct) values were
calculated by the Rotor-Gene Q Software (version
2.0.2). All quantitative real-time PCR reactions were
run in technical triplicates for each of the 3 patient and
2 control cell lines and mean ct-values for each
reaction were taken into account for calculations.
Protein biochemistry
To obtain homogenate from cultures, cells were lysed
and homogenized in lysis buffer (150 mM NaCl, 1%
Triton X-100, 50 mM Tris–HCl, pH 8.0) containing
protease inhibitor (Roche). Cell debris and nuclei were
removed by centrifugation at 3200 rpm for 10 min.
Protein concentration was determined by Bradford
protein assay. Proteins were separated by SDS-PAGE
and blotted onto nitrocellulose membranes (GE
Healthcare). Immunoreactivity was visualized using
HRP-conjugated secondary antibodies and the
SuperSignal detection system (Pierce).
Statistic
Statistical analysis was performed with GraphPad
Prism 7. Data are shown as mean ± SEM. For
comparisons, analysis of variance (ANOVA) was
performed followed by post hoc tests for within group
comparisons (Dunn’s test, or Bonferroni test). For
comparisons of two independent groups, student’s t-
tests was used. Statistically significant differences are
indicated in the figures by *p B 0.05, **p B 0.01 and
***p B 0.001.
qRT PCR quantification—Relative quantification is
based on internal reference genes to determine virtual
mRNA levels of target genes. Cycle threshold (ct) values
were calculated by the Rotor-Gene Q Software (version
2.0.2). Ct values were transformed into virtual mRNA
levels according to the formula: virtual mRNA level =
10 * ((ct(target) - ct(standart))/slope of standard curve).
Western blot quantification—Evaluation of bands
from Western blots (WBs) was performed using
ImageJ. Three independent experiments were per-
formed and blots imaged using a MicroChemi Imag-
ing System from Biostep. The individual bands were
selected and the integrated density was measured. All
WB bands were normalized to b-Actin and the ratios
averaged.
Immunocytochemistry—For cell culture experi-
ments, 10 cells of each condition were imaged. The
signal intensity of immuno-reactive signals was
quantified using ImageJ software.
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